GlaxoSmithKline Update: Influenz... ( LONDON and RESEARCH TRIANGLE PARK N.C...)

GlaxoSmithKline Update: Influenza A (H1N1)

Date:5/1/2009

LONDON and RESEARCH TRIANGLE PARK, N.C., May 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain.

The company has developed a number of potential interventions which it believes may be of value in efforts to reduce the impact and spread of this new influenza virus. These include the antiviral medicine Relenza (zanamivir) and significant vaccine capability and technology, including use of novel adjuvants.

To ensure continuity of supply and manufacture of all its critical medicines and vaccines, GSK has also invoked its own internal pandemic preparedness plan.

Relenza (zanamivir)

GSK has been working with governments to supply Relenza, for use in a pandemic situation, since the global spread of avian influenza (H5N1) which began in 2003. Relenza has typically been used to diversify and add to government stockpiles of Tamiflu (oseltamivir).

Since 2003, Relenza has been supplied to 26 governments for the purposes of pandemic stockpiling and on average the product constituted 13% of these stockpiles. Prior to the recent outbreak, the last significant order for Relenza was for 10.6 million treatment packs, which was delivered to the UK Government in April 2009.

In relation to the new influenza A (H1N1) strain, the WHO reported that the viruses obtained from the recent human cases were sensitive to oseltamivir and zanamivir but resistant to amantadine and remantadine.(1)

GSK has therefore contacted governments around the world to ascertain demand for Relenza, including those countries most affected by the virus, such as Mexico and the USA. As a result, GSK
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
2. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
3. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
4. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
5. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
6. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
7. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
8. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
9. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
10. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
11. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists

Post Your Comments:

GlaxoSmithKline Update: Influenz...( LONDON and RESEARCH TRIANGLE PARK N.C...),Health